NOVAMAB
Novamab focuses on the research and development of new nanobodies. The core members of the team have 15 years of experience in nanobody research and development, and are domestic nanobody "pioneers". At present, they have established an inhaled macromolecular drug research and development platform, an albumin nanobody long-acting platform and a nanobody double-antibody platform, etc., to give full play to nanobody The advantages of antibodies, the development of innovative nanobody drugs such as sprays and eye drops, to solve the pain points of clinical major chronic diseases in terms of administration methods, administration cycles, etc.
NOVAMAB
Industry:
Biotechnology Pharmaceutical Product Research Therapeutics
Founded:
2017-01-01
Status:
Active
Total Funding:
100 M CNY
Investors List
Tigeryeah Capital
Tigeryeah Capital investment in Series A - Novamab
Tianhui Chuangtou
Tianhui Chuangtou investment in Series A - Novamab
Fuho Capital
Fuho Capital investment in Series A - Novamab
More informations about "Novamab"
Novamab - Crunchbase Company Profile & Funding
Novamab focuses on the research and development of new nanobodies. The core members of the team have 15 years of experience in nanobody research and development, and are …See details»
About-Novamab
With a solid foundation in sdAb research and development for more than 10 years, Novamab has established the first and only sdAb development platform covering the full biopharmaceutical …See details»
Shanghai Novamab Biopharmaceuticals Co., Ltd. - BIO …
Jun 6, 2023 · Shanghai Novamab Biopharmaceuticals Co., Ltd is an innovative biopharmaceutical company dedicated to the development of novel nanobody drugs for patients all over the …See details»
Novamab Company Profile 2024: Valuation, Funding & Investors
Developer and provider of nano-antibody pharmaceuticals intended to serve the pharmaceutical industry. The company's medical research areas include tumors, autoimmune and …See details»
Shanghai Novamab Biology, the world's first inhaled nanobody …
Novamab was founded in 2017, focusing on the development of inhaled nanobody drugs. The company has now established a complete R&D, CMC, and pilot production system, built five …See details»
Company News-Novamab
On December 18,2023, Shanghai Novamab Biopharmaceuticals Co., Ltd. (hereinafter referred to as: "Company or Novamab") successfully completed completed a Series B financing of over …See details»
Novamab to Speak at ACCESS CHINA Partnering Forum
Oct 12th, 2023 (Shanghai) — We are glad to announce that Dr. Yakun Wan, the founder, Chairman, and CEO of Novamab, has been invited to present at ACCESS CHINA Partnering …See details»
Novamab - Funding, Financials, Valuation & Investors - Crunchbase
Novamab is funded by 7 investors. Jiu Yu Capital and Qiming Venture Partners are the most recent investors. in funding over 3 rounds. Their latest funding was raised on Jun 7, 2024 from …See details»
Shanghai Novamab Biopharmaceuticals - VentureRadar
Novamab Biopharmaceuticals is specialized in innovative nanobody new drugs and is devoted to developing better drugs for patients. Novamab has built a rich R&D pipeline covering …See details»
World's First Inhaled Nanobody Drug LQ036 - Medicilon
Recently, Shanghai Novamab Biopharmaceuticals Co., Ltd. (Novamab), LQ036 - recombinant anti-IL-4Rα single-domain antibody nebulizer (Pichia pastoris), a core drug for the treatment of moderate to severe asthma, was successfully …See details»
International Conference 及2024 BIO International Convention …
Novamab is dedicated to the research and development of nanobody drugs, with a strong foundation in the field of respiratory diseases. We continuously expand international …See details»
A novel inhalable nanobody targeting IL-4Rα for the treatment of …
Nov 20, 2023 · Capitalizing on the distinctive advantages of nanobodies (Nbs) in maintaining efficacy during storage and administration, we sought to develop a novel inhalable IL-4Rα Nb …See details»
Series B - Novamab - 2023-12-18 - Crunchbase Funding Round …
Dec 18, 2023 · Novamab raised $14019347 on 2023-12-18 in Series B. Start Free Trial . Chrome ExtensionSee details»
Recombinant anti-IL-4Rα nanobody(Shanghai Novamab …
Nov 21, 2024 · Now, its global highest R&D status is Phase 2, Mechanism: IL-4Rα inhibitors(Interleukin-4 receptor subunit alpha inhibitors), Therapeutic Areas: Immune System …See details»
Novamab will present the latest progress of its promising …
Novamab has developed dozens of sdAb drugs, covering respiratory, anti-infection, ophthalmology and oncology. Currently, it has obtained three clinical approvals. LQ036 and …See details»
The race to make COVID antibody therapies cheaper and more …
Oct 23, 2020 · Antibodies are a key component of the body’s natural immune response to SARS-CoV-2, and researchers have been racing to develop therapies that harness their ability to …See details»
LQ-060 - Drug Targets, Indications, Patents - Synapse - Patsnap
LQ-060, Initially developed by Shanghai Novamab Biopharmaceuticals Co., Ltd., Now, its global highest R&D status is Discovery, Therapeutic Areas: Immune System Diseases,Digestive …See details»
Novamab: LQ036 Completes The First Patient Dosing in Phase IIa …
LQ036 is an inhaled nanobody drug targeting IL-4Rα, independently developed by Novamab with its own intellectual property rights, for the treatment of asthma and COPD. LQ036 can …See details»
LQ-043H - Drug Targets, Indications, Patents - Synapse - Patsnap
Nov 21, 2024 · LQ-043H: a TSLP modulators Drug, Initially developed by Shanghai Novamab Biopharmaceuticals Co., Ltd., Now, its global highest R&D status is Phase 1, Mechanism: …See details»
Novamab:Systematic Opportunities for Antibody Inhalation …
Companies such as Novamab Biotechnology, AstraZeneca, and Zaiding Pharmaceuticals have made phased progress in the inhalation or skin administration of antibody drugs.See details»